AGRX
Agile Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 1.48
- Prev close
- 1.51
- Mkt cap
- 889.10K
- Vol
- 119.29K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.44
- High
- 1.51
- Forward P/E
- 0.27
- Beta
- 1.50
- Short ratio
- 0.28
- Inst. own
- 10.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.91428
- 200-d avg
- 1.89
- 1y target
- 5.00
Key statistics
- Market cap
- 889.10K
- Enterprise value
- 573.31K
- Trailing P/E
- 0.04
- Forward P/E
- 0.27
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.00
- EPS (TTM)
- 7.31
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -69.72%
- Revenue (TTM)
- 19.98M
- Revenue growth
- 121.90%
- Free cash flow
- -4.36M
- Total cash
- 2.87M
- Total debt
- 2.52M
- Return on equity
- 0.00%
- Shares outstanding
- 2.96M
- Short % of float
- 7.50%
- 50-day average
- 0.91428
- 200-day average
- 1.89
Analyst view
Consensus: hold
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 2023 | Maxim Group | up | Hold | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Agile Therapeutics, Inc.
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
- Country
- United States
- Website
- agiletherapeutics.com
News
- Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
- Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
- AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
- Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
- Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
- Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Your note
Sign in to keep a note on AGRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTOMARI ALFRED | Chief Executive Officer | Stock Award(Grant) | Jun 27, 2023 | 47,749 |
| BARBARI SHARON SURREY A | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| CARSON SANDRA | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| COIANTE SCOTT M | Chief Financial Officer | Stock Award(Grant) | Oct 2, 2023 | 20,080 |
| CONWAY ROBERT G. | Officer | Stock Award(Grant) | Jun 27, 2023 | 13,529 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Jun 7, 2023 | 976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.33% | 122,000 | 359.90K | Jun 29, 2023 |
| State Street Corporation | 0.56% | 10,843 | 31.99K | Jun 29, 2023 |
| Blackrock Inc. | 0.31% | 6,061 | 17.88K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.14% | 2,712 | 8.00K | Jun 29, 2023 |
| Investor AB | 0.09% | 1,754 | 5.17K | Jun 29, 2023 |
| Royal Bank of Canada | 0.04% | 758 | 2.24K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,098 | 15.53K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.20% | 3,765 | 11.11K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 502 | 1.90K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 295 | 767 | Aug 30, 2023 |